Lauren E. Colbert, Sarah B. Fisher, Claire W. Hardy, William A. Hall, Burcu Saka, Joseph W. Shelton, Aleksandra V. Petrova, Matthew D. Warren, Brooke G. Pantazides, Khanjan Gandhi, Jeanne Kowalski, David A. Kooby, Bassel F. El-Rayes, Charles A. Staley III, N. Volkan Adsay, Walter J. Curran Jr, Jerome C. Landry, Shishir K. Maithel and David S. Yu Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma Cancer 119
Version of Record online: 29 MAY 2013 | DOI: 10.1002/cncr.28144
Low expression of mixed lineage kinase domain-like protein (MLKL) in patients with resected pancreatic adenocarcinoma is associated with decreased overall survival in those who undergo surgical resection and with decreased recurrence-free and overall survival in the subset of patients receiving adjuvant chemotherapy. MLKL warrants further exploration as a potential prognostic biomarker in patients with resected pancreatic adenocarcinoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field